Research Update

RNS Number:1589X
Lombard Medical Technologies PLC
19 January 2006





  Lombard Medical reports new data demonstrating that its AorfixTM stent graft
            reduces the risk of endoleaks in angulated necks



London, UK, 19 January 2006 - Lombard Medical Technologies PLC (AIM: LMT)
reports today the publication of an abstract in the Vascular journal by
Jean-Noel Albertini, MD et al. at the Vascular Surgery Department, Hospital
Robert Debre, Reims, France.  The study concluded that the Company's AorfixTM
stent graft was the only device which did not develop endoleaks, regardless of
the angulation of the neck of the abdominal aorta.



Proximal endoleaks are an important risk factor following stenting of abdominal
aortic aneurysms.  The risk of leak increases as the angle of the proximal 
'neck' increases.  AorfixTM is a new flexible stent graft designed to overcome
this issue.  The aim of this study was to compare the endoleak flow rate (EFR)
in relation to neck angle between the AorfixTM and other manufactured stent
grafts.



EFRs corresponding to 10 neck angles between 0 and 70 degrees were measured.
Eight stent grafts were tested: AorfixTM (Lombard), Ancure (Guidant,
Indianapolis, IN), Powerlink(R) (Endologix, Irvine, CA), AneuRx(R) (Medtronic,
Sunnyvale, CA), Excluder(R) (W.L. Gore & Associates, Flagstaff, AZ), ZenithTM
and Zenith-FlexTM (Cook Inc., Bloomington, IN), and Lifepath (Edwards
Lifesciences, Irvine, CA).



For all stent grafts except the AorfixTM, the EFR was greater than at baseline
for neck angle >/= 30 degrees (p < .01).  The EFR at neck angle >/= 30 degrees
was lower with the AorfixTM compared with the other stent grafts (p < .01).



Neck angle had no influence on the EFR with the AorfixTM.  The AorfixTM may
decrease the incidence of proximal type 1 endoleak in patients with a severely
angulated aortic neck.



Alistair Taylor, Executive Chairman of Lombard, commented:



"It is very pleasing to see the publication of this report endorsing the
benefits of our AorfixTM stent graft.  There is a growing body of evidence to
suggest that AorfixTM is the only stent graft that can successfully treat
abdominal aortic aneurysms in severely angulated necks."



Enquiries:

Lombard Medical Technologies PLC
Tel: [phone]
Alistair Taylor, Executive Chairman
Brian Howlett, Chief Executive Officer



Financial Dynamics
Tel: [phone]
David Yates / John Gilbert



Notes to editors

Lombard Medical Technologies is a medical devices company developing stent
grafts and other medical products for use in the treatment of vascular disease.
The Company's lead product, AorfixTM, is a stent graft for the treatment of
aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated,
may rupture and cause death.  Abdominal and thoracic aortic aneurysms are the
13th largest cause of death in the US and the market is estimated to be worth
approximately US$2 billion by 2010.  AorfixTM is currently being commercialised
in the EU, with US clinical trials expected to commence during 2006.  The
Company has a strategic collaboration with one of the world's leading medical
devices companies, Boston Scientific.



Lombard Medical has recently successfully completed its initial public offering
on AIM and was admitted to listing in December 2005, raising #23.9 million, net
of expenses.  The Company, based in Oxfordshire & Yorkshire, currently employs
47 people.



Further background on the Company can be found at www.lombardmedical.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RESBKLFFQFBXBBD